Targeted Inactivation of the IL-4 Receptor α Chain I4R Motif Promotes Allergic Airway Inflammation by Blaeser, Frank et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/10/1189/12 $8.00
Volume 198, Number 8, October 20, 2003 1189–1200
http://www.jem.org/cgi/doi/10.1084/jem.20030471
 
1189
 
Targeted Inactivation of the IL-4 Receptor 
 
 
 
 Chain I4R 
Motif Promotes Allergic Airway Inﬂammation
 
Frank Blaeser,
 
1 
 
Paul J. Bryce,
 
2
 
 Nga Ho,
 
1
 
 Vidya Raman,
 
1
 
 Fatma Dedeoglu,
 
2
 
 
 
Debra D. Donaldson,
 
3
 
 Raif S. Geha,
 
2
 
 Hans C. Oettgen,
 
2 
 
and Talal A. Chatila
 
1,4
 
1
 
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110
 
2
 
Department of Pediatrics, Harvard Medical School, Boston, MA 02115
 
3
 
Department of Respiratory Disease, Wyeth Research, Cambridge, MA 02140
 
4
 
Department of Pathology and Immunology and the Center for Immunology, Washington University School of 
Medicine, St. Louis, MO 63110
 
Abstract
 
The insulin/interleukin-4 (IL-4) receptor (I4R) motif mediates the association of insulin receptor
substrate (IRS)-2 with the interleukin-4 (IL-4)R
 
 
 
 chain and transduces mitogenic signals in
response to IL-4. Its physiological functions were analyzed in mice with a germline point
mutation that changed the motif’s effector tyrosine residue into phenylalanine (Y500F). The
Y500F mutation abrogated IRS-2 phosphorylation and impaired IL-4–induced CD4
 
 
 
 T lympho-
cyte proliferation but left unperturbed Stat6 activation, up-regulation of IL-4-responsive gene
products, and Th cell differentiation under Th2 polarizing conditions. However, in vivo the
Y500F mutation was associated with increased allergen-induced IgE production, airway respon-
siveness, tissue eosinophilia, and mucus production. These results define an important role for
the I4R motif in regulating allergic inflammation.
Key words: interleukin 4 receptor • targeted mutagenesis • immunoglobulin E • 
insulin receptor substrate • asthma
 
Introduction
 
Interleukin-4 (IL-4) plays a key role in the development
of Th2 responses and the evolution of immediate hyper-
sensitivity reactions. IL-4 promotes the proliferation and
survival of lymphocytes, Th2 lineage commitment of CD4
 
 
 
T helper cells, and immunoglobulin isotype switching to
IgE. It also exerts direct effects on antigen-presenting cells
and on nonhematopoietic cells such as airway epithelial
and smooth muscle cells. The actions of IL-4 are medi-
ated by heterodimeric receptor complexes that have in
common a 140-kD 
 
 
 
 subunit (IL-4R
 
 
 
) that binds to and
transduces growth-promoting and transcription-activating
functions of IL-4 (1–3). In hematopoietic cells, IL-4R
 
 
 
associates with the 
 
 
 
c chain, a subunit common to several
cytokine receptors (4–6; for review see reference 7). IL-4R
 
 
 
also pairs with the IL-13R
 
 
 
1, which is expressed on he-
matopoietic and nonhematopoietic cells to mediate sig-
naling by both IL-4 and IL-13 (8). Targeted disruption of
the IL-4R
 
 
 
 subunit in mice abrogates the IgE response,
consistent with its central role in mediating allergic in-
flammation (9).
IL-4R
 
 
 
, 
 
 
 
c, and IL-13R
 
 
 
1 physically associate with spe-
cific members of the Janus family of protein kinases, Jak1,
Jak3, and Jak2 orTyK2, respectively, that serve to couple
ligand binding to intracellular activation events (10). Binding
of IL-4 to IL-4R
 
 
 
 chain is followed by receptor heterodimer-
ization and activation of Jak kinases by transphosphorylation
(11, 12). Activated Jak kinases mediate the phosphorylation
of the cytoplasmic tail of IL-4R
 
 
 
 on conserved tyrosine
residues that serve as docking sites for downstream Src
homology domain (SH)2 and phosphotyrosine-binding
domain (PTB) signaling proteins. Three closely clustered
tyrosine residues serve as docking sites for Stat6, an SH2
domain–containing transcription factor selectively coupled
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Abbreviations used in this paper:
 
 AHR, airway hyperresponsiveness; AID,
activation-induced cytidine deaminase; BAL, bronchoalveolar lavage;
CSR, class switch recombination; DC-PCR, digestion-circularization
PCR; ES, embryonic stem; GLT, germline transcripts; I4R, insulin/IL-4
receptor; IL-4, interleukin-4; IRS, insulin receptor substrate; ITIM,
immunoreceptor tyrosine-based inhibitory motif; PI3-K, phosphatidyl-
inositol 3
 
 
 
-kinase; PTB, phosphotyrosine-binding domain; SH, Src ho-
mology domain; SHP, SH2-containing tyrosine phosphatase.T
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to the IL-4R, which is indispensable for the induction of
gene expression by IL-4, including the 
 
 
 
1 and 
 
 
 
 heavy chain
germline transcription (13). A distal tyrosine residue at the
COOH terminus of IL-4R
 
 
 
 defines an immunorecptor ty-
rosine-based inhibitory motif (ITIM) that binds SH2 do-
mains of several phosphatases, including the SH2-containing
tyrosine phosphatase (SHP)-1 and SHP-2 and inositol 5
 
 
 
phosphatase (14, 15).
The sequence surrounding the proximal tyrosine 500
(Y500) residue in the cytoplasmic tail of the murine IL-4
 
 
 
chain defines a motif that is highly homologous with se-
quences in the insulin and insulin-like growth factor 1 re-
ceptors (16). This motif, referred to as the insulin/IL-4 re-
ceptor (I4R) motif, interacts upon its phosphorylation at
Y500 with several PTB domain–containing adaptor pro-
teins that couple the IL-4R
 
 
 
 to downstream signaling cas-
cades. In hematopoietic cells, the insulin receptor substrate
(IRS)-2 is the most prominent phospho-I4R substrate (17,
18). However, phospho-I4R also interacts with other
PTB-containing adaptors including IRS-1 (16), FRIP/
Dok-R (19), and Shc (20). Recruitment of IRS-2 to IL-
4R
 
 
 
 leads to IRS-2 phosphorylation, the subsequent re-
cruitment and activation of PI3-K, and the activation of
the down-stream protein kinase Akt (17, 21–23). Studies
using mutant IL-4R
 
 
 
 chains transfected into cells lines and
IRS-2–deficient lymphocytes have implicated the I4R mo-
tif and the IRS-2 signaling pathway in transmitting mito-
genic signals in response to IL-4 (16, 18, 23, 24). Further-
more, a role for this motif in human allergic disorders has
been suggested by a polymorphism in the human receptor,
S503P, that strongly associates with atopy, asthma, and air-
way hyperresponsiveness (AHR) (25–27). In this study, we
addressed the role of the I4R motif in IL-4 receptor signal-
ing in vivo by introducing a germline mutation in the mu-
rine IL-4R
 
 
 
 gene that results in replacement of Y500 with
a phenylalanine.
 
Materials and Methods
 
Construction of Targeting Vector and Generation of Mutant Mice.
 
Genomic DNA used to construct the targeting vector were iso-
lated from a bacterial artificial chromosome clone containing the
murine IL-4R
 
 
 
 gene (Genome Systems) (28). The replacement-
type targeting vector (pKO; Lexicon) contained 13.5 kb of
 
IL4RA
 
 sequences that extended from a XhoI site proximal to
exon 9 to a KpnI site distal to exon 12 of the gene. A single
A
 
→
 
T substitution was introduced by site-directed mutagenesis
(QuickChange; Stratagene) at the second position of the tyrosine
500 codon (TAC), corresponding to position 1735 of murine IL-
4R
 
 
 
 cDNA (1). The mutation changed the codon specificity
from tyrosine to phenylalanine (TTC). Except for the Y500F
mutation, the exonic sequences in the targeting vector were con-
firmed by DNA sequencing to be identical to those of the native
allele. Positive selection of targeted clones was provided by a
floxed PGK-
 
neo
 
 cassette that was subcloned into an EcoRI site
engineered by site-directed mutagenesis within intron 11 73 bp
upstream of exon 12. The targeting vector also included a Diph-
theria toxin gene (pKO SelectDT V840; Lexicon) to select
against random integration.
Targeting plasmids were introduced by electroporation into
RW4 embryonic stem (ES) cells and subjected to G418 selection.
Homologous recombination was ascertained by Southern blotting
using a probe corresponding to exon 4 of 
 
IL4RA
 
, which lies 5
 
 
 
 to
the homology sequence. Neomycin gene insertion is associated
with the introduction of a new EcoRI site, leading to a decrease
in the size of the genomic EcoRI fragment that normally hybrid-
izes with the probe from 12.5 kb to 8.5 kb (see Fig. 1). Success-
fully targeted clones were transiently transfected with a Cre re-
combinase to remove the inserted neomycin gene, leaving in
place one loxP sequence flanked by EcoRI sites.
Heterozygous ES cells were injected into C57BL/6 blastocysts,
and resultant male chimeras were mated with BALB/c females.
Offspring were screened for heterozygotes by Southern blotting
and PCR analysis. Heterozygotes were further bred for 8–10
generations on BALB/c background. Homozygous mutant mice
and WT littermate controls were generated by mating Het par-
ents. WT BALB/c and IL-4R
 
 
 
 knock-out mice (BALB/c-
 
Il4ra
tm
 
1Sz
 
) were obtained from the Jackson laboratory. All protocols
were in accordance with NIH guidelines and approved by the
Animal Care and Use Committee of Washington University
School of Medicine.
 
PCR Analysis.
 
Screening of WT and mutant 
 
IL4RA
 
 alleles
was performed by PCR amplification using genomic DNA and
the following allele-specific forward (F) primers: 5
 
 
 
-TTGCAGA-
CAATCCTGCCTA-3
 
 
 
 (WT-specific) and 5
 
 
 
-TTGCAGACA-
ATCCTGCCTT-3
 
 
 
 (mutant–specific), and a common reverse
(R) primer: 5
 
 
 
-ACTGCCTGCACAAACTCCT-3
 
 
 
. Primers used
for PCR screening of the residual LoxP-containing allele were: F,
5
 
 
 
-GGTGTCTATTTTAGGTGCC-3
 
  
 
and
 
 
 
R, 5
 
 
 
-TCTTCTC-
TCTTACTCTGTGCT-3
 
 
 
.
For RT-PCR analysis, total RNA was extracted from sple-
nocytes of WT and IL-4R
 
 
 
 Y500F mutant mice using TRIzol
(GIBCO BRL). The RNA was treated with Dnase I to remove
residual genomic DNA contamination and then reverse tran-
scribed. 
 
IL4RA
 
 transcripts were amplified by a two step process
using the following pairs of nested primers: outer pair F
(exon 11), 5
 
 
 
-CAGACCCGAAGCCAGGAGTCAACC-3
 
 
 
 and
R (exon 12), 5
 
 
 
-CCCTGCTTCACTGCCTGCACAAAC-3
 
 
 
;
inner pair F (both exon 12), 5
 
 
 
-GAGCAGCCTTCACA-
CCAG-3
 
 
 
 and R, 5
 
 
 
-ACTGCCTGCACAAACTCCT. For
 
GAPDH
 
 transcripts, the primers were F, 5
 
 
 
-ACCACAGTC-
CATGCCATCAC-3
 
 
 
 and R, 5
 
 
 
-TCCACCACCCTGTTGC-
TGTA-3
 
 
 
. For class switch recombination (CSR) studies, RNA
was isolated from splenocytes that have been either left un-
treated or treated for 48 h with IL-4 at 50 ng/ml (R&D Sys-
tems) or with anti-CD40 mAb (clone HM40–3; BD Bio-
sciences) plus IL-4. Primers used for RT-PCR amplification of
germline, postswitch, and activation-induced cytidine deami-
nase (AID) transcripts were described previously (29). GAPDH
transcripts were amplified as an internal control using the fol-
lowing primers: F, 5
 
 
 
-ACCACAGTCCATGCCATCAC-3
 
 
 
and R, 5
 
 
 
-TCCACCACCCTGTTGCTGTA-3
 
 
 
. All PCR re-
actions were performed on various dilutions of cDNA to ensure
that the products measured were in the linear range. Depending
on the PCR product being measured, 5–30 ng of cDNA fell
within this range.
 
Digestion-circularization (DC)–PCR.
 
Genomic DNA was iso-
lated from cultured splenic B cells stimulated for 6 d with anti-
CD40 mAb
 
 
 
 IL-4. DNA was digested with EcoR1, circularized,
and used as template for PCR using primers as reported previ-
ously for S
 
 
 
-S
 
 
 
1 and nicotinic acetylcholine receptor unit
(AChR) (30) and for S
 
 
 
-S
 
 
 
 (31).T
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Flow Cytometry Analysis.
 
Single cell suspensions were stained
with the indicated antibodies and analyzed on a FACSCalibur
 
®
 
cytometer (Becton Dickinson). FITC- or PE-conjugated mAbs
used were anti-TCR
 
 
 
 (H57), CD3 (145–2C11), CD4 (L3T4),
CD8 (53–6.7), CD23 (B3B4), CD124 (mIL4R-M1), B220
(RA3–6B2), and anti I-A
 
d
 
 (AMS-32.1) (BD Biosciences).
 
Lymphocyte Cultures and In Vitro Th Cell Differentiation.
 
Sple-
nocytes were fractionated into CD4
 
 
 
 T cells or B cells by mag-
netic-activated cell sorting using isolation kits for the respective
lymphocyte population (Miltenyi Biotec). Purified B cells were
 
 
 
97% B220
 
 
 
 and 
 
 
 
1% TCR
 
 
 
 
 
, and CD4
 
 
 
 T cells were 
 
 
 
85%
TCR
 
 
 
 
 
/CD4
 
 
 
 and 
 
 
 
1% B220
 
 
 
. T and B lymphocyte cultures
(5 
 
 
 
 10
 
5
 
 cells/well in 96-well flat-bottomed plates) were treated
with the indicated mitogens for 48 or 72 h, respectively. The fol-
lowing mitogens were used: anti-TCR
 
 
 
 mAb and anti-CD40
mAb (BD Biosciences), F(ab
 
 
 
)
 
2
 
 goat anti–mouse IgM antibodies
(Jackson ImmunoResearch Laboratories), PMA and ionomycin
(Sigma-Aldrich), recombinant IL-4 (Peprotech), and IL-2 (Bio-
logical Resources Branch, National Cancer Institute). The cul-
tures were pulsed with 0.4 
 
 
 
Ci/well of 
 
3
 
H-TdR for 18 h and
then harvested. Proliferation was measured as counts per minute
incorporated.
T cell blasts were generated by culturing splenocytes on plates
coated with anti-TCR
 
 
 
 mAB (10 
 
 
 
g/ml) for 3 d followed by
expansion of cell cultures with IL-2 (100 U/ml) for 7 d. Induc-
tion of in vitro IgE production was accomplished by culturing
splenocytes for 7 d with anti-CD40 mAB in the presence of IL-4
at 100 ng/ml. For in vitro Th cell differentiation, splenocytes
were cultured for 3 d on anti-TCR
 
 
 
–coated plates in the pres-
ence of IL-4 (100 ng/ml) and anti-IFN-
 
 
 
 mAb (10 
 
 g/ml) (Th2
conditions) or IL-12 (1 ng/ml) and anti–IL-4 mAb (10  g/ml)
(Th1 conditions) (R&D Systems). The cultures were expanded
for an additional 4 d with IL-2 (100 U/ml) after which the cells
were washed and restimulated with plate-coated anti-TCR 
mAb for 48 h. Culture supernatants were assayed for IL-4, IL-5,
IL-13, and IFN-  by ELISA (IL-4 and IFN- ; PharMingen and
IL-5 and IL-13; R&D Systems).
Immunoblotting and Immunoprecipitation. Cells were stimulated
with IL-4 (100 ng/ml) for the indicated periods of time and then
lysed with either 2  Laemmli gel loading buffer or 0.5% NP-40
detergent buffer (32). Whole cell lysates or immunoprecipitates
derived from NP-40 detergent extracts were resolved by SDS/
PAGE, transferred to nitrocellulose filters, and immunoblotted
with the respective antibodies: anti-Dok1, Dok-R, IL-4R , Shc
and Stat6, (Santa Cruz Biotechnology, Inc.), anti–phospho-Akt
(serine 473), Akt, phospho-Shc (tyrosine 239/240), phospho–
Stat-6 (tyrosine 641), and phosphotyrosine (Cell Signal), anti–
phospho–Jak-1 (tyrosine 1022/1023) and Jak-1 (Sigma-Aldrich),
and anti–IRS-2 (Upstate Biotechnology). The blots were devel-
oped using horseradish peroxidase–conjugated secondary anti-
bodies and enzyme-linked chemiluminescence (ECL; Amersham
Biosciences).
Immunizations. Mice were injected i.p. on day 0 with 100  g
OVA in alum together with 300 ng of pertussis toxin in a final
volume of 100  l. They were reimmunized on day 14 with 100
 g OVA in alum. Saline control groups of mice were similarly
treated except for inclusion of saline in place of OVA.
Measurement of Immunoglobulin Levels. Total immunoglobulin
levels were determined by ELISA. The standard BD Biosciences
protocol for sandwich ELISA was used to quantify OVA-specific
IgE Abs (33). Results of OVA-specific IgE were expressed as ng
per milliliter by comparison with a standard consisting of purified
mouse OVA-specific IgE secreted by the hybridoma TO , a gift
from Mamoru Kiniwa (Immunology Research Laboratory, Hanno
Research Center, Taiho Pharmaceutical Co. Ltd.). For OVA-
specific antibodies of other isotypes, pooled sera from five mice
that had been immunized i.p. with OVA were aliquoted and used
as an ELISA reference. For each IgG subclass, a dilution of this
standard serum was prepared and arbitrarily assigned a concentra-
tion of 1 U/ml. Standard curves constructed using this reference
were used to calculate the amounts of OVA-specific antibody in
test samples.
Analysis of Bronchoalveolar Lavage Fluid. Cells in the airways
were recovered by flushing 0.8 ml of bronchoalveolar lavage
(BAL) fluid (1 mM EDTA, 10% FCS, PBS) into the lungs via the
trachea. Total cell counts were determined, and 100  l of fluid
was cytospun onto glass slides. Differential cell counts were per-
formed after staining with Diff-Quik Stain Set (Baxter Health-
care Corp.) (34). 
Measurement of Airway Hyperresponsiveness.  OVA-immunized
mice were exposed to aerosolized OVA (1% in saline for 20 min
by ultrasonic nebulization) on days 28, 29, and 30, and their lung
function was tested on day 31 after their initial immunization. For
IL-4 and IL-13 instillation, 5  g of the respective cytokine in 50
 l of PBS buffer were administered daily for three consecutive
days. Control instillation was performed using 5  g BSA in 50  l
PBS. Lung function was measured 24 h after the last cytokine or
BSA instillation. Enhanced pause (Penh) was measured using
whole body plethysmography (BUXCO) (34). Increases in air-
way resistance to aerosolized methacholine were determined as
Penh values.
Statistical Analysis. Student’s t test was used to compare the
groups of mice. Where appropriate, Penh results were analyzed
by two-way ANOVA. A P value smaller than 0.05 was consid-
ered statistically significant.
Results
Generation of IL-4R  Y500F Mutant Mice by Targeted
Knock-in Mutagenesis. A targeting construct was designed
to replace exon 12 of IL4RA of ES cells with another bear-
ing an A→T single base pair substitution at the second po-
sition of the Y500 codon that changed the codon specific-
ity from tyrosine to phenylalanine (28) (Fig. 1 A). This
mutation has previously been demonstrated to abro-
gate pY500-dependent binding of PTB domain–contain-
ing adaptor proteins to the I4R motif and consequently to
uncouple downstream signaling pathways activated via
pY500 (16, 18). Successfully targeted ES clones were used
to derive murine male chimera that transmitted the Y500F
mutation into the germline (Fig. 1 B). Matings of IL-4R 
Y500F heterozygotes resulted in generation of Y500F ho-
mozygous mutant mice in numbers consistent with autoso-
mal recessive Mendelian inheritance. Homozygous mutant
mice of both sexes were phenotypically indistinguishable
from their WT and heterozygous littermates. The transmis-
sion and integrity of the mutant allele was verified by sev-
eral methods including Southern blot analysis, allele-spe-
cific PCR amplification, and direct sequencing of genomic
DNA (Fig. 1, B and C).
RT-PCR analysis revealed that the mutant allele was
transcribed at levels equivalent to those of the WT allele
(Fig. 1 D). The presence of the A→T substitution in mu-T
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tant transcripts was directly confirmed by sequencing of the
RT-PCR products. (Fig. 1 D). Expression of mutant re-
ceptor protein was verified by flow cytometry to be closely
matched to WT controls (Fig. 1 E). Analysis revealed the T
and B lymphocytes of the IL-4R  Y500F mutant mice to
be normal in number and phenotype (unpublished data).
The Y500F Mutation Abrogates IRS-2 Activation. The
impact of the Y500F mutation of IL-4R  signaling events
was examined in T and B lymphocyte populations treated
with IL-4. Treatment of splenic T lymphoblasts with IL-4
revealed that Jak1 kinase activation was normally induced
(Fig. 2 A). However, phosphorylation of IL-4R  was
markedly decreased in the Y500F mutant lymphocytes
compared with WT controls, consistent with Y500 being
a major target of phosphorylation by Jak kinases (Fig. 2 A).
Significantly, the Y500F mutation abrogated the tyrosine
phosphorylation of IRS-2 in response to IL-4 treatment,
indicating failure to recruit IRS-2 to the mutant receptor
(Fig. 2 B). In contrast, IL-4–induced phosphorylation of
Dok-R (FRIP), a PTB domain protein reported previ-
Figure 1. Targeted knock-in
mutagenesis of murine IL-4R 
gene. (A) Targeting strategy. WT
exon 12 was replaced with one carry-
ing an A to T substitution in the
second position of codon 500 in
exon 12 of IL4RA, changing its
specificity from a tyrosine (Y) to a
phenylalanine (F). The mutant exon
is marked with an asterisk. Successful
targeting introduced within intron
11 a floxed Neo cassette flanked by
EcoRI sites. Subsequent treatment
with Cre recombinase removed the
neo cassette, leaving one loxP se-
quence and the EcoRI site in place.
Restriction enzyme abbreviations:
B, BamHI; R, EcoRI; and X, XhoI.
   and    denote no-coding and
coding exonic sequences, respec-
tively. (B) Southern blot analysis of
EcoRI-digested mouse tail genomic
DNA of WT, heterozygous (HET),
and homozygous (HOMO) mutant
mice. The introduction of a novel
EcoRI site in intron 11 of targeted
IL4A reduces the size of an EcoRI
genomic fragment detected with an
exon 4 probe from 12.5 kb in the
WT allele to 8.5 kb in the mutant
allele. (C) PCR analysis of mouse tail
DNA using Y500 and F500 allele-
specific primers (top and middle,
respectively) or primers spanning
the residual 34-bp loxP site left in
intron 11 after Cre-mediated excision
of the floxed Neo cassette. (D,
top)  RT-PCR analysis of IL-4R 
mRNA expression in splenocytes of
WT and Y500F homozygous mutant
mice. Amplified GAPDH transcripts
were used as controls. (Bottom) Se-
quence analysis of RT-PCR products
of IL-4R  transcripts of WT and
Y500F mutant mice. (E) Flow cyto-
metric analysis of IL-4R  expres-
sion in IL-4R Y500F lymphocytes.
Splenic B cells of WT, IL-4R 
knock-out, and IL-4R  Y500F mice
were stained with PE-conjugated rat
antimurine IL-4R  mAb (mIL4R-M1).
Control staining was performed on
WT splenic B cells using a PE-con-
jugated, isotype-matched rat IgG2a
antibody.T
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ously to associate with phospho-Y500/I4R (19), was un-
affected. This indicated that phosphorylation of Dok-R by
IL-4 can proceed in a phospho-Y500–independent man-
ner. IRS-2 phosphorylation results in the recruitment and
activation of phosphatidylinositol 3 -kinase (PI3-K) and
activation of the downstream kinase Akt, which play an
important role in IL-4–induced proliferation (35). The lat-
ter event is associated with the phosphorylation of Akt on
serine 473. In Y500F T lymphocytes, Akt activation by
IL-4 was abrogated as evidenced by the failure of IL-4
treatment to induce Akt phosphorylation on serine 473
(Fig. 2 C). In contrast to the failure to activate the IRS-2/
Akt pathway in Y500F, activation of Stat-6 was unaf-
fected. Tyrosine phosphorylation of Stat-6 in response to
IL-4 proceeded equally well in WT and mutant T lym-
phocytes (Fig. 2 D).
Impairment of the IRS-2 signaling cascade was also
noted in IL-4–treated Y500F primary splenic B cells in
which induction of IRS-2 phosphorylation by IL-4 was
abolished (Fig. 2 E). The specificity of this finding was
demonstrated using another PTB domain adaptor protein,
Dok1, which was found constitutively phosphorylated in B
cells. When normalized for protein content, its phosphory-
lation level was marginally increased after IL-4 treatment
but without appreciable difference between WT and mu-
tant B cells (Fig. 2 E).
B cells express the p46/p52 isoforms of Shc, a PTB do-
main–containing adaptor that exhibits low affinity binding
to IL-4R  pY500 relative to IRS proteins (36). IL-4 treat-
ment induces Shc phosphorylation in some tissues includ-
ing B cells (37), prompting examination of Shc phosphory-
lation in response to IL-4 treatment of WT and Y500F B
cells. In WT B cells, IL-4 treatment induced sustained
phosphotyrosine phosphorylation of the p46 isoform (Fig.
2 F). IL-4 also induced p46 Shc phosphorylation in Y500F
mutant B cells but with reduced intensity. In contrast, the
p52 isoform was constitutively phosphorylated in both cell
types and was not affected by IL-4 treatment. These results
indicated partial dependence of p46 Shc phosphorylation
by IL-4 on the Y500 residue.
Figure 2. The Y500F mutation selectively impairs activation of the IRS-2/AKT signaling cascade. (A–D) IL-4–induced signaling events in WT and
Y500F T cells. (A) Jak1 and IL-4R  tyrosine phosphorylation. (Top) Lysates of T cell lymphoblasts were directly blotted with an anti–phospho-Jak1
antibody (pJak1) then reprobed with an anti-Jak1 protein antibody. (Bottom) IL-4R  immunoprecipitates were probed with an antiphosphotyrosine
antibody (pY-IL-4R ) then reprobed with an anti–IL-4R  antibody. The IL-4R  Y500 lysates were overloaded to reveal low level phosphorylation of
mutant IL-4R  in response to IL-4 treatment. (B) IRS-2 and Dok-R tyrosine phosphorylation. IRS-2 and Dok-R immunoprecipitates were probed
with an antiphosphotyrosine antibody followed by anti–IRS-2 and anti–Dok-R antibodies, respectively. (C) Akt phosphorylation. Cell lysates were
directly blotted with an anti–phospho-Akt serine 473 antibody (pAkt) and then reprobed with an anti-Akt protein antibody. (D) Time course of Stat6
phosphorylation. Stat6 immunoprecipitates were probed with an anti–phospho-Stat6 antibody (pY-Stat6) and then reprobed with an anti-Stat6 antibody.
(E–H) IL-4–induced signaling events in WT and Y500F splenic B cells. (E) Tyrosine phosphorylation of IRS-2 (left) and Dok1 (right). (F) p46Shc phos-
phorylation. Lysates were probed with anti–phospho-Shc antibody and then reprobed with an anti-Shc antibody. (G) Akt phosphorylation on serine 473.
(H) Time course of Stat6 phosphorylation.T
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Failure of IL-4 treatment to induce IRS-2 phosphoryla-
tion in Y500F mutant B cells was associated with abroga-
tion of downstream Akt activation (Fig. 2 G). In contrast,
induction by IL-4 of Stat-6 phosphotyrosine phosphoryla-
tion was not impaired (Fig. 2 H). These results established
that in both T and B lymphocytes the Y500F mutation ab-
rogated the activation by IL-4 of the IRS-2–dependent sig-
naling cascade, whereas sparing other cascades activated via
IL-4R .
The Y500F Mutation Impairs IL-4–induced CD4  T Cell
Proliferation. The role of the Y500 residue in transducing
mitogenic signals in lymphocytes was examined in splenic
CD4  T cells and B cells of WT and Y500F mutant mice.
Fig. 3 A shows that in contrast to WT CD4  T cells,
which exhibited a modest proliferative response to IL-4,
the response of mutant T cells was substantially decreased.
Significantly, the Y500F mutation abrogated the comitoge-
nic function of IL-4 in supporting T cell proliferation in-
duced by anti-TCR antibodies. This effect was specific in
that the response to stimulation with anti-TCR antibodies
and IL-2 or with phorbol ester PMA and the calcium iono-
phore ionomycin was not affected.
IL-4 also induced a modest proliferative response in pu-
rified B cells that, unlike the case in CD4  T cells, was not
compromised by the Y500F mutation (Fig. 3 B). Further-
more, the Y500F mutation did not impact the capacity of
IL-4 to support B cell proliferation induced by B cell mito-
gens including anti-CD40 and anti-IgM antibodies (Fig. 3
B). These results established that the Y500 pathway is se-
lectively required to support IL-4 mitogenic function in T
but not B lymphocytes.
The impact of the Y500F mutation on the up-regulation
of classical IL-4 responsive genes was examined by deter-
mining the expression levels of CD23 and the MHC class
II antigen I-Ad in IL-4–treated WT and Y500F B cells. Fig.
3 C demonstrates that the Y500F mutation had no effect
on the up-regulation by IL-4 of CD23 and I-Ad. This is
consistent with previous observations that the up-regula-
tion by IL-4 of CD23 and MHC class II antigens proceeds
in a Stat-6–dependent manner (38, 39).
Impact of Y500F Mutation on Th Cytokine Production.
The impact of the Y500F mutation on Th cell differentia-
tion was examined by comparing the in vitro differentiation
of WT and Y500F T cells into Th1 or Th2 effector lym-
phocytes in the presence of IL-12 and IL-4, respectively.
There was no significant difference in IL-4, IL-5, or IL-13
production between WT and Y500F T cells that have been
differentiated under Th2 polarizing conditions and then
stimulated by T cell receptor engagement (Fig. 4 A). Simi-
larly, there was no significant difference in IFN-  produc-
tion between WT and Y500F T cells that have been differ-
entiated under Th1 conditions. However, the residual
production of all three Th2 cytokines was significantly de-
creased in Y500F T cell cultures that have been differenti-
ated under Th1 polarizing conditions compared with their
WT counterparts. This suggests that the Y500 pathway
modulates Th cell differentiation by promoting the persis-
tence of Th2 cells in the context of Th1 skewing conditions.
The impact of Y500F mutation on Th cytokine produc-
tion was further analyzed in mice immunized with OVA
mixed with alum, a Th2-promoting adjuvant. Lymphocytes
of WT and IL-4R  Y500F mutant mice that have been im-
munized with OVA proliferated equally well upon in vitro
stimulation with OVA (unpublished data). Furthermore,
splenocytes and LN cells of OVA-immunized WT and IL-
4R  Y500F mutant mice produced similar amounts of
IL-4, IL-5, IL-13, and IFN-  upon stimulation with OVA
in vitro (Fig. 4 B). These results indicated that the Y500F
mutation did not compromise Th2 cell differentiation in the
context of a Th2-biased in vivo immune response.
The Y500F Mutation Enhances Antibody Responses. The
impact of the Y500F mutation on humoral immunity was
Figure 3. Effect of the Y500F mutation on IL-4–induced lymphocyte
proliferation and gene expression. (A) T cell proliferation. (Left) CD4 
splenic T cells of WT and homozygous Y500F littermate mice were
cultured with plate-bound anti-TCR  mAb (100 ng/ml) and IL-4 as
indicated. Proliferation was assessed by 3H-thymidine incorporation.
Results are mean responses of triplicate cultures   SE and are representa-
tive of three experiments. (Right) Purified CD4  T cells were cultured
with PMA (25 ng/ml) and ionomycin (1  M) or with plate-bound anti-
TCR  and IL-2 (100 U/ml). (B) B cell proliferation. (Left) Splenic B cells
were cultured with anti-CD40 mAb (1  g/ml) and IL-4 as indicated. (Right)
Splenic B cells were cultured with IL-4 (10 ng/ml), anti-IgM antibodies
(10  g/ml), or IL-4 and anti-IgM antibodies as indicated. (C) IL-4–induced
up-regulation of CD23 and MHC class II antigens. Splenic B cells were
cultured for 48 h in the absence (thin line) or in the presence (thick line)
of IL-4 at 50 ng/ml and then examined for CD23 and I-Ad expression by
flow cytometry. Results are representative of five experiments.T
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examined by determining the total and antigen-specific an-
tibody responses after immunization with OVA mixed
with alum adjuvant to promote Th2-type responses (40),
or with saline/alum as immunization control. Fig. 5 A re-
veals that Y500F mutant mice exhibited substantially
higher total IgE levels than WT controls both after immu-
nization with OVA/alum and after control injection of sa-
line/alum (2.5- and 7-fold, respectively). In contrast, the
levels of IgM, IgG1, 2a, 2b, and 3 isotypes were similar.
Significantly, OVA-specific antibody responses of several
isotypes, including IgG1, IgG2a, and IgE, were three- to
five-fold higher in the IL-4R  Y500F mutant mice com-
pared with control (Fig. 5 B). In contrast, levels of OVA-
specific IgM, IgG2b, IgG3, and IgA were not significantly
different in WT and mutant mice.
Enhanced IgE production was also observed upon in
vitro stimulation of naive Y500F splenocytes with anti-
CD40 mAb and IL-4, which induce isotype switching to
IgE and IgG1 independent of T cell help. Under optimal
stimulation conditions, the Y500F splenocytes produced
about threefold higher amount of IgE compared with sple-
nocytes of WT littermate controls. In contrast, both WT
and Y500F cells produced similar amounts of IgG1 (Fig. 6
A). These results indicated that the enhanced IgE antibody
responses in the IL-4R  Y500F mutant mice reflected, at
least in part, altered B cell responsiveness to IL-4.
To elucidate the mechanism of enhanced IgE produc-
tion, we analyzed the induction of molecular events associ-
ated with CSR. These include expression of C  and C 1
germline transcripts (GLT), expression of the gene for AID
followed by S →S  and S →S 1 deletional switch re-
combination, and expression of mature I -C  and I -C 1
transcripts (41). Fig. 6 B demonstrates that the Y500F mu-
tation was associated with enhanced induction of   germ-
line transcripts (GLT) in splenic B cells stimulated for 48 h
with anti-CD40mAb   IL-4.  1 GLT were only modestly
increased with IL-4, whereas   GLT were unaffected. In
contrast, both   and  1 postswitch transcripts (I →C 1
and I →C , respectively) were markedly increased in
Y500F splenic B cells stimulated with anti-CD40 mAb  
Figure 4. Impact of the Y500F mutation
on Th cytokine production. (A) In vitro Th
cell polarization. Naive WT and Y500F
splenic T cells were differentiated into Th1
or Th2 cells and then stimulated with anti-
TCR  mAB for 48 h. Culture supernatants
were then harvested and examined for IL-4,
IL-5, IL-13, and IFN-  production by
ELISA. (B) Cytokine production in response
to antigenic stimulation. Splenocytes and
mesenteric LN cells of OVA-immunized
WT and Y500F mice were cultured for 4 d
in the presence of 50  g/ml of OVA. Culture
supernatants were assayed for IL-4, IL-5,
IL-13, and IFN-  by ELISA. In both panels,
results are means   SE (n   4–5 mice/group)
and are representative of three experiments.
*P   0.001; **P   0.013; ***P   0.002.
Figure 5. The Y500F mutation
up-regulates total IgE production
and antigen-specific IgG1, IgG2a,
and IgE antibody responses. Mice
were immunized with OVA (100  g)
mixed with alum or sham immu-
nized with saline/alum on day 0 and
14. Total (A) and OVA-specific Ig
isotypes (B) were determined on day
28 postimmunizations by ELISA.
Results are means   SE (n   6/group).T
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IL-4 compared with WT control B cells. The increased
levels of   and  1 postswitch transcripts in Y500F splenic B
cells were associated with heightened expression of AID,
an enzyme that plays an obligate role in CSR and somatic
hypermutation (29). Treatment with IL-4 alone or with
anti-CD40   IL-4 induced higher levels of AID transcripts
in mutant compared with WT B cells.
Further evidence of enhanced CSR to the  1 and  
heavy chain loci in Y500F mutant B cells was obtained by
DC-PCR amplification. The results showed enhanced S -
S 1 and S -S  deletional switch recombination in anti-
CD40 mAB   IL-4–treated Y500F B cells compared with
similarly treated WT B cells (Fig. 6 C). Neither stimulus
induced these events by itself (unpublished data). Overall,
these results indicated that the Y500F mutation potentiated
molecular mechanisms involved in switching to both  1
and   loci. The observation that in vitro IgE but IgG1 syn-
thesis was increased in Y500F B cells treated with anti-
CD40   IL-4 in the face of an early surge in both  1 and  
postswitch transcripts is most likely due to subsequent se-
quential switching from  1 to   (42).
Potentiation of Allergen-induced Airway Inflammation by the
Y500F Mutation. The functional consequences of Y500F
mutation were further analyzed in a model of antigen-
induced airway inflammation. Mice immunized i.p. with
OVA then challenged by OVA inhalation develop an
IL-4R –dependent allergic inflammatory airway response
characterized by AHR to methacholine, eosinophilic infil-
tration, and goblet cell hyperplasia. Accordingly, mice were
immunized with OVA then subjected to inhalation chal-
lenge with OVA. Fig. 7 A reveals that at baseline, both WT
and mutant mice immunized with OVA exhibited similar
Penh. OVA-sensitized IL-4R  Y500F mutant mice ex-
posed to aerosolized OVA exhibited significantly enhanced
bronchial responses to methacholine compared with simi-
larly treated WT littermates (P   0.03). In contrast, both
WT and mutant mice sham immunized with saline/alum
and then exposed to aerosolized OVA exhibited an equally
modest increase in Penh upon methacholine challenge.
The enhanced bronchial responsiveness observed in
OVA-treated Y500F mutants was accompanied by an ex-
aggerated allergic inflammatory response. Examination of
lung tissue of WT and mutant mice stained with hematox-
ylin and eosin revealed patchy peribronchial inflammatory
infiltrates, composed primarily of eosinophils and lympho-
cytes, that were substantially more intense in OVA-sensi-
tized and challenged Y500F mutant mice compared with
WT controls (Fig. 7 B). In contrast, sham-immunized mice
exposed to aerosolized OVA showed normal lung histol-
ogy (unpublished data). Analysis of BAL fluid of OVA-sen-
sitized and challenged mice revealed that OVA-sensitized
Y500F mutants exhibited greater recruitment of eosino-
phils into the airways compared with similarly treated WT
mice (Fig. 7 C). In contrast, the two strains of mice exhib-
ited similar numbers of eosinophils in the peripheral blood
(unpublished data).
Allergen-driven inflammation of the airways is often ac-
companied by goblet cell metaplasia. IL-4 and IL-13 are me-
diators of this response, which proceeds in an IL-4R –
dependent manner (43–46). Significantly, the IL-4R  Y500F
mutants exhibited markedly increased goblet cell metaplasia
with mucus overproduction, revealed by periodic acid–
Schiff staining, compared with controls (Fig. 7 D). These re-
sults indicated that the Y500F mutation exaggerated anti-
gen-induced airway allergic inflammatory responses.
To determine whether the airways of Y500F mutant
mice are intrinsically more responsive to signaling via IL-
4R , we examined their response to direct IL-4 and IL-13
instillation compared with WT control mice. AHR mea-
sured after intranasal instillation of IL-4 was not signifi-
cantly different between WT and the IL-4R  Y500F mu-
tant mice (Fig. 7 E). AHR induced by IL-13 instillation
was significantly decreased at higher concentrations of
methacholine challenge in Y500F mutant mice compared
Figure 6. The Y500F mutation augments isotype switching. (A) Produc-
tion of IgG1 and IgE by cultured splenocytes treated with an anti-CD40
mAb   IL-4. Levels of IgG1 and IgE antibodies present in IgG1 and IgE
in supernatants of unstimulated cells were  8 ng/ml, respectively. Results are
means   SE antibody (4 mice/group). Similar results were found in three
separate experiments. (B) Molecular events in isotype switching. RT-PCR
analysis of  ,  1, and   germline (GLT) and  1 and   postswitch transcripts
(I → 1 and I → , respectively) in splenic B cells treated for 48 h with
IL-4, anti-CD40 mAB, or both. Results are representative of four pairs of
WT and mutant mice from two independent experiments. (C) S -S 1
and S -S  deletional switch recombination measured by DC-PCR at day
6 after treatment with anti-CD40 mAb   IL-4. PCR was performed
using 5 ng (lanes 1 and 3) or 20 ng (lanes 2 and 4) of template DNA.T
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with WT controls. Treatment with both cytokines was as-
sociated with a modest, predominantly neutrophilic inflam-
matory cell population in the BAL fluid that was not signif-
icantly different between WT and IL-4R  Y500F mutant
mice (Fig. 7 F). These results indicated that the enhanced
AHR observed in OVA-sensitized and challenged IL-4R 
Y500F mutant mice was likely due to the exaggerated al-
lergic inflammatory response rather than to increased re-
sponsiveness of resident airway cells to IL-4 and IL-13.
Discussion
By using mice with a point mutation in the germline
that targets the effector tyrosine residue of the I4R motif,
an important role for this motif was revealed in the regula-
tion of IL-4R –dependent immune responses in vivo.
Mutagenesis of the Y500 residue resulted in the uncou-
pling of IL-4R  from the IRS-2 pathway and its down-
stream components PI3-K/Akt. It also resulted in impaired
CD4  T cell proliferation in response to IL-4. However,
rather than dampening IL-4R –dependent responses in
vivo, the Y500F mutation enhanced antigen-specific anti-
body responses and allergic airway inflammation, consistent
with a previously unrecognized negative regulatory func-
tion of the I4R motif in in vivo allergic responses.
The targeting strategy specifically inactivated Y500-
dependent signaling while leaving unperturbed signaling
via other tyrosine residues in the cytoplasmic domain of IL-
4R . Of the adaptor molecules implicated previously in
docking at the I4R motif, only IRS-2 was completely un-
coupled from IL-4R  by Y500 mutagenesis. IL-4–induced
tyrosine phosphorylation of Dok-R was not impaired, sug-
gesting a redundant function of Y500 in its recruitment.
Shc phosphorylation was attenuated but not abrogated, in-
dicating partial dependence on Y500 for IL-4–induced Shc
activation. Other signaling events that are mediated by IL-
4R  in a Y500-independent manner proceeded unim-
paired, including Jak kinase activation and Stat6 tyrosine
phosphorylation,
Consistent with studies implicating signaling pathways
downstream of IL-4R  Y500 in cell proliferation, the mi-
togenic response of IL-4R  Y500F CD4  T cells to IL-4
was greatly decreased and comitogenesis with anti-TCR
antibodies abolished. A previous observation that IRS-2–
deficient lymphocytes exhibit impaired IL-4–induced pro-
liferation implicates failure of IRS-2 activation in the de-
fective IL-4 mitogenic response of IL-4R  Y500F T cells
(23). Surprisingly, however, a proliferative defect was not
observed in B cells treated with IL-4 alone or in combina-
tion with anti-CD40 or anti-IgM antibodies. IL-4–induced
Figure 7. The Y500F mutation enhances AHR, tissue
eosinophilia, and goblet cell metaplasia in an antigen-
induced model of allergic airway inflammation. (A)
AHR to aerosolized methacholine in WT and Y500F
mutant mice (n   5–6/group) immunized with OVA/
alum or sham immunized with saline/alum mix and
then subsequently challenged with aerosolized OVA.
AHR was assessed by enhanced respiratory pause
(Penh). Results are means   SE; †P   0.03 (versus
IL-4R  Y500F OVA). (B) Differential count of in-
flammatory cells found in BAL fluid of mice tested in
A. *P   0.04 (versus IL-4R  Y500F OVA). (C) Lung
histology of WT and IL-4R  Y500F mutant mice sen-
sitized and challenged with OVA. H&E, hematoxylin-
eosin; PAS, periodic acid-schiff reagent. (D) The number
of mucin-positive cells in the bronchi of OVA-treated
WT and Y500F animals. PAS-stained lung sections
were scored for the number of mucin-secreting cells
per high power field (HPF, 400 ) in central medium-
sized bronchi. Three representative fields were counted
for each of three mice in each group. **P   0.0001
(versus IL-4R  Y500F OVA). (E) AHR to aerosolized
methacholine in WT and Y500F mutant mice (n  
14–15 mice/group) tested after intranasal instillation of
IL-4, IL-13, or BSA at 5  g each. (F) Differential count
of inflammatory cells found in BAL fluid of mice tested in
E. §P   0.03; ¶P   0.016 versus IL-4R  Y500F IL-13 at
100 and 333 mg methacholine/ml, respectively.T
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IRS-2 and Akt phosphorylation was similarly abrogated in
IL-4R  Y500F T and B cells, ruling out both signaling in-
termediates as the immediate locus of this discrepancy. The
rescue of IL-4 mitogenic function in IL-4R  Y500 B cells
suggests compensation by a currently unknown adaptor or
signaling intermediate that is activated in a Y500-indepen-
dent manner.
Given the critical function of Y500-coupled pathways in
IL-4–induced T cell mitogenesis, the Y500F mutation
would have been expected to impair evolution of a Th2-
type, IL-4R – dependent immune response by restricting
IL-4–dependent expansion of antigen-specific lymphocyte
populations. However, differentiation into Th2 cells pro-
ceeded unimpaired both in vitro in response to Th2 polar-
izing signals and in vivo in response to a Th2-promoting
antigenic stimulus (OVA mixed with alum) (40). This indi-
cated that the Y500F mutation did not restrict Th2 cell dif-
ferentiation under these experimental paradigms in agree-
ment with previous studies on CD4  T cells made to
express I4R mutant IL-4R  chains by retroviral transduc-
tion (47). However, decreased residual Th2 cytokine secre-
tion was observed in Y500F that have been differentiated
under Th1 polarizing conditions. This suggests a role for
the Y500-coupled pathways in supporting Th2 cell differ-
entiation and/or expansion that becomes limiting only un-
der polarizing Th1 conditions. Further studies will be re-
quired to verify this proposition.
The Y500F mutation augmented the production of anti-
gen-specific IgG1 and IgE antibodies associated with Th2
responses and antigen-specific IgG2a antibodies, which are
normally associated with Th1-type immunity but are sup-
pressed in Th2-type responses (40, 48). The up-regulation
by the Y500F mutation of antigen-specific antibody re-
sponses was not associated with altered Th cytokine pro-
duction, since the magnitude of the antigen-induced IL-4,
IL-5, IL-13, and IFN-  production was similar in WT and
mutant lymphocytes. In contrast, the Y500F mutation up-
regulated in vitro IgE production and augmented molecu-
lar events associated with CSR in response to treatment
with anti-CD40 mAb and exogenously added IL-4. These
results suggest negative regulatory function of IL-4R 
Y500–coupled signaling pathways in B cell antibody pro-
duction. On the other hand, the enhanced antigen-specific
IgG2a antibody responses in the context of a Th2-type im-
mune response implicate the I4R motif in the suppression
of Th1-associated antibody isotypes. Switching to IgG2a is
dependent on the transcription factor T-bet (49). I4R sig-
naling may alter the activity of this pathway and/or other
pathways involved in switching to IgG2a.
The Y500F mutation enhanced allergen-induced AHR,
tissue eosinophilia, and goblet cell metaplasia, consistent
with a regulatory function of the I4R motif in allergic in-
flammation. Induction of AHR and inflammation is an IL-
4R –dependent process involving hematopoietic and resi-
dent airway cells. In particular, induction of AHR, goblet
cell metaplasia and mucin production is a direct attribute of
IL-4R  signaling in airway epithelial cells. Both IL-4 and
IL-13 act directly on resident epithelial cells to induce gob-
let cell metaplasia in a Stat-6–dependent manner but inde-
pendent of recruitment of hematopoietic inflammatory
cells (46). AHR induced by cytokine instillation in the air-
ways was either similar (IL-4) or decreased (IL-13) in IL-
4R  Y500F mutants compared with WT controls, indicat-
ing that the enhanced allergen-induced AHR and goblet
cell metaplasia in the Y500F mutants was not due to
heightened IL-4R  responses in airway tissues. Rather, it
incriminates the augmented allergic inflammatory response
as the most likely mechanism. This may involve enhanced
production by mast cells and basophils of IL-4 and IL-13
due to increased antigen-specific IgE antibody levels and/
or altered recruitment to the airways of inflammatory cells
including eosinophils and allergen-specific Th2 T cells.
In the human IL-4R , there exists a serine to proline
polymorphism in the I4R motif (S503P), six amino acids
down-stream of the effector tyrosine residue (Y497). The
presence of the more common serine residue is associated
with elevated IgE levels, atopy, and asthma in humans, a
phenotype that strongly overlaps with that of mice with
targeted inactivation of the I4R motif (25–27). An adverse
effect of the S503 relative to the P503 substitution on the
function of the I4R motif of the human IL-4R  chain
would provide a mechanism by which this and perhaps
other IL-4R  polymorphic amino acid residues promote
human allergic disorders.
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